Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
Single Arm-Studies suggest improved remission and survival rates for a Protocol with Mitoxantron 10mg/m2 for 3 days combined with AraC 1g/m2 bid on days 1+3+5+7 compared to a conventional DA 7+3 protocol (45mg/m2 Daunorubicin).
Epistemonikos ID: 0cb5a60b1091b6d4db7e828949d87efbe40f0e90
First added on: Jan 21, 2022